AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02711267
Drug: 5% Zovirax® cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (manufactured by GlaxoSmithKline Pharma in Canada, distributed in the USA by Valeant Pharmaceuticals North America LCC, Bridgewater,NJ 08807)
Trial: NCT02711267
Drug: 5% Aciclostad cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (STADA Arzneimittel GmbH, Vienna, Austria)
Trial: NCT00136565
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m², D1, 4 cycles
Trial: NCT02711267
Drug: 5% Aciclovir cream 1A Pharma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (1A Pharma GmbH, Vienna, Austria)
Trial: NCT02711267
Drug: 5% Zovirax Cold Sore Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (GlaxoSmithKline Consumer Health Care, Brendfort, UK; Marketing authorization holder: Beeham Group PLC, Brendfort, UK)
Trial: NCT02711267
Drug: 5% Zovirax® cream (Austria)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (GlaxoSmithKline Pharma GmbH, Vienna, Austria)
Trial: NCT00250198
Drug: STA-5326
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00136565
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1200 mg/m², D1, 4 cycles
Trial: NCT00447265
Drug: Lupus Treatment- Standard of Care
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized standard of care treatment for lupus with corticosteroids and with mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA)
Trial: NCT00447265
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00910065
Drug: D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV dose of aspirin at a dose of 500 mg as bolus infusion injection in approximately 30 seconds through the vein on Day 1.
Trial: NCT00910065
Drug: D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 250 mg IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV dose of aspirin at a dose of 250 mg as bolus infusion injection in approximately 30 seconds through the vein on Day 1.
Trial: NCT00910065
Drug: Acetylsalicylic acid (Aspirin, BAYe4465) 300 mg Tablet
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose of aspirin tablet at a dose of 300 mg on Day 1.
Trial: NCT02060526
Drug: Recombinant human heparan N-sulfatase [rhHNS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant human heparan N-sulfatase \[rhHNS\]
Trial: NCT01607580
Drug: low-dose glucocorticoid Methylprednisolone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients receive low-dose glucocorticoid from day 5 post transplant
Trial: NCT02342574
Drug: F901318
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of active compound
Trial: NCT02342574
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of placebo
Trial: NCT03949634
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doxorubicin is 60 mg/m2 intravenously on Days 1 of each 21-day cycle followed by cyclophosphamide.
Trial: NCT01612988
Drug: BOMP
RxNorm normalized name: Bleomycin, Oncovin (vincristine), Methotrexate, and Prednisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day-8 OMB prephase:~Ofatumumab 300 mg IV day -8 Methylprednisolone 100 mg TD IV day -8~BOMP cycle 1 and 2 :~Ofatumumab 1000 mg IV day 1 and day 15 Bendamustine 70mg IV day 2 and ady 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3 Methylprednisolone 100 mg TD IV day 15~BOMP cycle 3 to 6 :~Ofatumumab 1000 mg IV day 1 Bendamustine 70mg IV day 2 and day 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3
Trial: NCT03414099
Drug: Ketum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketum (Mitragyna speciosa) is an indigenous plant of Southeast Asia reported to have medicinal value in traditional culture
Trial: NCT03414099
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drink matched for taste and appereance
Trial: NCT03176953
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-active medication
Trial: NCT00446680
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo BD for 6 months
Trial: NCT03504527
Drug: triple combinations
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled budesonide(160ug,bid),formotero(4.5ug,bid) and tiotropium bromide(18μg,qd)
Trial: NCT00225810
Drug: Crohn's Disease
RxNorm normalized name: Humira Pen 40 MG/0.8 ML - Crohn's Disease Starter Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03708354
Drug: placebo softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 430 mg olive oil softgel daily for 24 weeks. Each placebo softgel of 430 mg olive oil will contain no tocotrienol or tocopherols at detectable levels.
Trial: NCT00927914
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets
Trial: NCT03504527
Drug: double combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled formotero(4.5ug,bid) and tiotropium bromide(18μg,qd)
Trial: NCT01456624
Drug: DW-ES(B)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 625mg
Trial: NCT00086268
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00147368
Drug: intravenous (IV) arginine
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02495636
Drug: MPDL3280A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPDL3280A 1200 mg will be administered intravenously every 3 weeks.
Trial: NCT03982134
Drug: PDR001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDR001 is a humanized IgG4 antibody
Trial: NCT00502411
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 17.5 mg/m\^2 IV bolus infusion, followed by continuous IV infusion on days 1-4.
Trial: NCT02594995
Drug: NBP
RxNorm normalized name: Tri-N-Butyl Phosphate (TNBP)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03544567
Drug: Oraxol
RxNorm normalized name: doxycycline hyclate Oral Capsule [Oraxyl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral paclitaxel will be supplied in capsules and oral HM30181A-US in tablets
Trial: NCT02156271
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00391209
Drug: simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient specific dose, inhaled, before meals,6 months
Trial: NCT00391209
Drug: intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient specific dose, inhaled, before meals, 6 months
Trial: NCT04049409
Drug: CMAB809
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMAB809 will be administered by IV infusion at a single dose of 6mg/kg.
Trial: NCT01774656
Drug: Pharmacological Treatment
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ recovery and titrated (against symptoms, potassium, and renal function) to the following maximum doses: lisinopril 40 mg daily; carvedilol 25 mg 3 times daily; spironolactone 25 mg daily; digoxin 125g daily, and losartan 150 mg daily.
Trial: NCT01439776
Drug: Vit D
RxNorm normalized name: Tri-Vit Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800IU/day
Trial: NCT00337727
Drug: Comparator; Placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dexamethasone 12mg Pbo tablets.
Trial: NCT00337727
Drug: Comparator; Placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant 80 mg \& 125 mg Pbo capsules.
Trial: NCT01965431
Drug: BI 207127 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04422899
Drug: AIV007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravitreal
Trial: NCT03546868
Drug: [18F]FSPG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 200 MBq of \[18F\]FSPG and undergo PET/CT for assessing disease activity in inflammatory bowel disease
Trial: NCT02730195
Drug: Tyrosine Kinase Inhibitor (TKI)
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given TKI therapy
Trial: NCT03354143
Drug: Standard Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg.
Trial: NCT01795768
Drug: AZD 4547
RxNorm normalized name: aspirin / hydrocodone bitartrate Oral Tablet [Azdone]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00755573
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regime as described for pregabalin
Trial: NCT02168569
Drug: Coartem™ (Artemether-lumefantrine combination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL (Coartem™) was administered twice daily for three days (six doses in total) with dosage determined according to body weight: one tablet (20mg artemether and 120mg lumefantrine) for children 5 to \<15kg, two tablets per dose for those 15 to \<25kg, and three tablets per dose for those 25 to \<35kg.
Trial: NCT02168569
Drug: Coarsucam™ (Amodiaquine-artesunate combination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AQ-AS (Coarsucam™) was administered once daily according to body weight: one 25mg artesunate and 67.5mg amodiaquine tablet in children \<9kg, one 50mg artesunate and 135mg amodiaquine tablet in children 9-17.9kg; and one 100mg artesunate and 270mg amodiaquine tablet in children \>18-35kg.
Trial: NCT00107484
Drug: ferumoxtran-10
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02491944
Drug: AZD9291
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 80 mg AZD9291 tablet on Day 1 administered orally with 240 mL water following an overnight fast.
Trial: NCT02910583
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules to match ibrutinib administered orally once daily
Trial: NCT02491944
Drug: [14C]AZD9291
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each healthy male subject will also receive a single, radiolabeled, 100 μg dose of \[14C\] AZD9291 administered as an IV microdose infusion starting at 5 hours and 45 minutes after receiving the oral dose.
Trial: NCT00985920
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).~The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues.
Trial: NCT02785770
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of matching placebo for PF-04447943 administered as an extemporaneously prepared solution
Trial: NCT01974739
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04172727
Drug: saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ultrasound-guided bilateral TFP block with 20 mL of saline 0.9%
Trial: NCT01759056
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00505778
Drug: Mesalamine Twice-Daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalamine tablets, 1.6-2.4 g/day, taken twice daily for 52 weeks
Trial: NCT03414892
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily, oral
Trial: NCT04250506
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as tablets for oral use.
Trial: NCT01857011
Drug: Intravenous Iron sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Iron Sucrose 200 mg in the immediate postoperative period and first day postop.
Trial: NCT01857011
Drug: Oral Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron(III)-hydroxide polymaltose complex 100 mg twice daily in the fist 8 postoperative weeks.
Trial: NCT01756651
Drug: Fentanyl pectin
RxNorm normalized name: Pectin
DrugBank: Pectin (DB11158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of Intranasal fentanyl 100mcg vs 200 mcg.
Trial: NCT02697344
Drug: R-(-)-Gossypol Acetic Acid
RxNorm normalized name: citronellol acetate, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04540016
Drug: [14C]HSK7653
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of \[14C\]HSK7653 (radioactivity of 80 µCi) capsules are taken under fasted condition.
Trial: NCT03247452
Drug: Polyethylene Glycol plus ascorbic acid
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 liters of Polyethylene Glycol plus ascorbic acid will be administered to both groups
Trial: NCT00545272
Drug: short acting β2-agonist
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg/ 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
Trial: NCT00530621
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, daily
Trial: NCT00927004
Drug: Etoricoxib (Arcoxia)
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg, daily dose, oral delivery, 14 days duration
Trial: NCT04028544
Drug: Qishenyiqi dropping pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: on the basis of standard treatment, adding QSYQ dropping pills 1 bag each time, 3 times a day
Trial: NCT04028544
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: on the basis of standard treatment, adding placebo 1 bag each time, 3 times a day
Trial: NCT03030976
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive cyclophosphamide (Cy) on day -2 and day -1 to reduce B cells. The dose is 0.5g/m2/d.
Trial: NCT02604849
Drug: Streptomycin
RxNorm normalized name: Streptomycin
DrugBank: Streptomycin (DB01082)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00423501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sc weekly
Trial: NCT03486015
Drug: 30% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of 30% glucose
Trial: NCT01331005
Drug: nepafenac 0.1% drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop three times per day for one year
Trial: NCT01074853
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT00903409
Drug: Simvastatin + Lovaza® (omega-3-acid ethyl esters)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label Simvastatin + Lovaza® (omega-3-acid ethyl esters) \[formerly known as Omacor\]
Trial: NCT02820324
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02713074
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will be subjected to normal saline (Sod. Chloride 0.9%, Nile) for vaginal cleaning
Trial: NCT04129437
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weight based ibuprofen dosing
Trial: NCT01311505
Drug: Myrin© 2 (Rifampicin + Isoniazid)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two (2) fixed-dose combination tablets each containing Rifampicin 150 mg and Isoniazid 75 mg
Trial: NCT01737593
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02160054
Drug: Graceptor®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01546623
Drug: TAP-144-SR(3M)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03288051
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine is administered if Mean arterial pressure drops below 65 mmHg. Mean arterial pressure must be maintained above 65 mmHg. Norepinephrine is titrated accordingly.
Trial: NCT01806259
Drug: Ketorolac 30 mg IV
RxNorm normalized name: ketorolac 30 MG
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active drug
Trial: NCT01806259
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo looking like the Active drug
Trial: NCT00892801
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken by mouth once a day, for 15 days, one day prior to initiation of whole brain radiation therapy at 5 or 10 mg/day during the phase I component. One of these doses will be selected as the maximum tolerable dose and will be selected for the phase II component
Trial: NCT02527577
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection Hour (H) 0, H12 ; H24, H36 ; H48
Trial: NCT02205840
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in each eye
Trial: NCT00870584
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of placebo for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.
Trial: NCT00093249
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20% lipid emulsion - vehicle) will be administered intravenously in a fashion identical to clevidipine as described above.
Trial: NCT00419445
Drug: GTS21/Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04507282
Drug: LMWH
RxNorm normalized name: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID 19 positive patients anticogulation level, subprophylactic level and prophylactic level
Trial: NCT02802917
Drug: SPF 50 Y49 091 (BAY 987516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
Trial: NCT02802917
Drug: SPF 50 X15 158 (BAY 987516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
Trial: NCT02802917
Drug: SPF 50 X15 160 (BAY 987516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
Trial: NCT02802917
Drug: SPF 50 X57 162 (BAY 987516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
Trial: NCT02121665
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
Trial: NCT02594566
Drug: CyMVectin
RxNorm normalized name: Cydectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CyMVectin will be delivered by unilateral intramuscular (IM) injection at Day 0, Day 28(+4 days), and Day 56 (+4 days) in alternating arms. Each dose of CyMVectin will be administered in a 1.0-mL volume
Trial: NCT00304213
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00680394
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 buccal misoprostol + matching placebo or 1600 buccal misoprostol
Trial: NCT00534313
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution, intravenous, placebo (double dummy), monthly, short-term = 24 weeks (6 months)
Trial: NCT00323830
Drug: Capecitabine, cisplatin, Radiotherapy (+/-)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine, cisplatin + Radiotherapy (randomized)
Trial: NCT01058707
Drug: MLN0128
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLN0128 capsules